These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28035396)

  • 21. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
    Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z
    Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
    Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
    Elife; 2014 Sep; 3():. PubMed ID: 25265470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
    Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
    Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lotus (Nelumbo nucifera) seedpod extract inhibits cell proliferation and induces apoptosis in non-small cell lung cancer cells via downregulation of Axl.
    Kim NY; Yang IJ; Kim S; Lee C
    J Food Biochem; 2021 Feb; 45(2):e13601. PubMed ID: 33381866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
    Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
    PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Matsui Y; Yamada T; Katayama Y; Hirai S; Sawada R; Tachibana Y; Ishida M; Kawachi H; Nakamura R; Nishioka N; Morimoto K; Iwasaku M; Horinaka M; Sakai T; Tokuda S; Takayama K
    Cancer Sci; 2024 Oct; 115(10):3333-3345. PubMed ID: 39039802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells.
    Lu Y; Wan J; Yang Z; Lei X; Niu Q; Jiang L; Passtoors WM; Zang A; Fraering PC; Wu F
    FASEB J; 2017 Apr; 31(4):1382-1397. PubMed ID: 28034848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
    Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
    Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
    Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
    J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
    Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
    Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
    Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
    Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.
    Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME
    Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.